Posted by Michael Wonder on 13 Apr 2016
Agenda for the 20 April 2016 TC meeting
13 April 2016 - The Transparency Commission will consider the reimbursement of Wakix (pitolisant), Busilvex (busulphan), Cosentyx (secukinumab), Anoro Ellipta (vilanterol trifenatate with umeclidinium bromide) & Noxafil (posaconazole). The Commission will also re-examine the SMR & ASMR of RoActemra (tocilizumab) and Herceptin (trastuzumab).
